Effect of fluconazole on plasma fluvastatin and pravastatin concentrations

[1]  U. Christians,et al.  Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[2]  S. Hall,et al.  The interaction of diltiazem with lovastatin and pravastatin , 1998, Clinical pharmacology and therapeutics.

[3]  U. Christians,et al.  Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? , 1998, Pharmacology & therapeutics.

[4]  N. Matsushima,et al.  An automated method for the simultaneous determination of pravastatin and its main metabolite in human plasma by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry. , 1998, Biomedical chromatography : BMC.

[5]  P. Neuvonen,et al.  Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations , 1998, Clinical pharmacology and therapeutics.

[6]  G. Koren,et al.  A model for the prediction of digoxin-drug interactions at the renal tubular cell level. , 1998, Therapeutic drug monitoring.

[7]  P. Neuvonen,et al.  Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid , 1998, Clinical pharmacology and therapeutics.

[8]  P. Neuvonen,et al.  Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole , 1998, Clinical pharmacology and therapeutics.

[9]  P. Neuvonen,et al.  PHARMACOKINETICS AND DISPOSITION , 1998 .

[10]  P. Neuvonen,et al.  Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid , 1996, Clinical pharmacology and therapeutics.

[11]  L. Wienkers,et al.  Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[12]  L. Wienkers,et al.  Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[13]  Jouni Ahonen,et al.  The Effect of the Systemic Antimycotics, Itraconazole and Fluconazole, on the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Midazolam , 1996, Anesthesia and analgesia.

[14]  P. Neuvonen,et al.  Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole , 1994, Clinical pharmacology and therapeutics.

[15]  T. Cyr,et al.  Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[16]  J. Quion,et al.  Clinical Pharmacokinetics of Pravastatin , 1994, Clinical pharmacokinetics.

[17]  M. Gill,et al.  Determination of fluconazole in human serum by solid-phase extraction and reversed-phase high-performance liquid chromatography. , 1992, Therapeutic drug monitoring.

[18]  F. Tse,et al.  Pharmacokinetics of Fluvastatin After Single and Multiple Doses in Normal Volunteers , 1992, Journal of clinical pharmacology.

[19]  C. Shear,et al.  Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. , 1991, The American journal of medicine.

[20]  S. Singhvi,et al.  Biotransformation of pravastatin sodium in humans. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[21]  S. Singhvi,et al.  Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. , 1990, British journal of clinical pharmacology.

[22]  M. Rinaldi,et al.  Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection , 1989, Antimicrobial Agents and Chemotherapy.

[23]  D. Back,et al.  In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. , 1988, British journal of clinical pharmacology.

[24]  C. Shear,et al.  Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. , 1991, Archives of internal medicine.

[25]  L. Kaminsky,et al.  Small intestinal cytochromes P450. , 1991, Critical reviews in toxicology.